News | October 30, 2023
Dr Reddy's Q2 FY24 PAT jumps 33% to Rs 1,480 Cr
Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter
Dr Reddy’s Laboratories recorded revenue of Rs 6,880.20 crore during the quarter
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Advances Amgen's mission to serve patients with rare disease medicines
Approval is for use in myelofibrosis patients with anaemia regardless of prior myelofibrosis therapy
Brian Foard will lead the Specialty Care GBU ad interim, effective immediately.
Guaifenesin extended-release tablets help to loosen phlegm (mucus) and thin bronchial secretions to rid the bronchial passageways of bothersome mucus and make coughs more productive
Combating the prevalent stigma against TB in the society, India has been committed to providing, enabling and patient-centric support to all, individuals suffering from TB
Good momentum in commercial CDMO business
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
However, PAT growth will be lower than operating profit growth mainly due to brand amortization expenditure on account of acquisition.
Subscribe To Our Newsletter & Stay Updated
